Equities research analysts expect Spark Therapeutics Inc (NASDAQ:ONCE) to report ($0.45) earnings per share for the current quarter, according to Zacks. Eight analysts have made estimates for Spark Therapeutics’ earnings, with the highest EPS estimate coming in at $1.41 and the lowest estimate coming in at ($1.71). Spark Therapeutics reported earnings per share of ($1.70) during the same quarter last year, which suggests a positive year over year growth rate of 73.5%. The business is scheduled to issue its next quarterly earnings results on Tuesday, May 8th.
According to Zacks, analysts expect that Spark Therapeutics will report full year earnings of ($3.42) per share for the current financial year, with EPS estimates ranging from ($6.21) to ($1.44). For the next year, analysts expect that the company will post earnings of ($4.32) per share, with EPS estimates ranging from ($6.09) to ($2.60). Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Spark Therapeutics.
Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings results on Tuesday, February 20th. The biotechnology company reported ($1.73) EPS for the quarter, meeting analysts’ consensus estimates of ($1.73). The company had revenue of $7.41 million during the quarter, compared to analysts’ expectations of $9.53 million. Spark Therapeutics had a negative return on equity of 59.38% and a negative net margin of 2,100.80%.
A number of analysts have recently commented on ONCE shares. Chardan Capital lowered their price target on Spark Therapeutics from $100.00 to $60.00 and set a “buy” rating for the company in a research note on Tuesday, December 12th. BMO Capital Markets set a $73.00 price target on Spark Therapeutics and gave the company a “buy” rating in a research note on Tuesday, December 12th. Cantor Fitzgerald set a $105.00 price target on Spark Therapeutics and gave the company a “buy” rating in a research note on Monday, December 11th. Raymond James Financial reissued a “buy” rating and set a $75.00 target price on shares of Spark Therapeutics in a research note on Thursday, December 7th. Finally, Barclays reissued a “buy” rating and set a $54.00 target price on shares of Spark Therapeutics in a research note on Wednesday, December 13th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and sixteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $70.58.
Shares of Spark Therapeutics (NASDAQ:ONCE) traded up $1.85 during mid-day trading on Friday, hitting $65.48. The stock had a trading volume of 508,390 shares, compared to its average volume of 763,648. The company has a market cap of $2,380.00, a PE ratio of -8.47 and a beta of 2.81. Spark Therapeutics has a one year low of $41.06 and a one year high of $91.75.
Several institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. grew its stake in shares of Spark Therapeutics by 1.4% during the 4th quarter. BlackRock Inc. now owns 2,650,258 shares of the biotechnology company’s stock worth $136,277,000 after acquiring an additional 35,801 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Spark Therapeutics by 15.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock worth $164,986,000 after acquiring an additional 241,016 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of Spark Therapeutics by 46.4% during the 3rd quarter. Janus Henderson Group PLC now owns 756,088 shares of the biotechnology company’s stock worth $67,413,000 after acquiring an additional 239,723 shares in the last quarter. Clearbridge Investments LLC grew its stake in shares of Spark Therapeutics by 2.9% during the 4th quarter. Clearbridge Investments LLC now owns 687,444 shares of the biotechnology company’s stock worth $35,348,000 after acquiring an additional 19,492 shares in the last quarter. Finally, Rock Springs Capital Management LP grew its stake in shares of Spark Therapeutics by 3.0% during the 4th quarter. Rock Springs Capital Management LP now owns 615,000 shares of the biotechnology company’s stock worth $31,623,000 after acquiring an additional 18,000 shares in the last quarter.
COPYRIGHT VIOLATION WARNING: “Zacks: Brokerages Anticipate Spark Therapeutics Inc (ONCE) to Post -$0.45 Earnings Per Share” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/03/14/zacks-brokerages-anticipate-spark-therapeutics-inc-once-to-post-0-45-earnings-per-share.html.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Get a free copy of the Zacks research report on Spark Therapeutics (ONCE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.